Tissue Regenix Group plc is a medical technology company. The Company is engaged in the development of regenerative products to make replacement native tissue using biological (human and animal) tissues. It operates through Cardiac, Wound Care and Orthopaedics divisions. Its decellularisation (dCELL) technology removes deoxyribonucleic acid and other cellular material from tissue leaving an acellular scaffold, which is not rejected by the patient's body. The dCELL has applications in wound care, heart valve replacement and knee repair. Its products portfolio includes DermaPure, which is used for the treatment of chronic or acute wounds; SurgiPure XD Surgical Tissue Matrix, which is used as a soft tissue patch for the surgical repair of damaged or ruptured soft tissue membranes; OrthoPure XM, which is used to replace the tissue removed during a partial meniscopy; OrthoPure XT, which is a decellurised porcine tendon, and CardioPure, a decellurised human pulmonary or aortic heart valve.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Symbol: LON:TRX
- CUSIP: N/A
- Web: www.tissueregenix.com/
Capitalization:- Market Cap: £91.04 million
- Outstanding Shares: 743,183,000
Average Prices:- 50 Day Moving Avg: GBX 13.09
- 200 Day Moving Avg: GBX 14.25
- 52 Week Range: GBX 10.88 - GBX 21
P/E:- Trailing P/E Ratio: N/A
- P/E Growth: 0.00
Sales & Book Value:- Annual Revenue: £1.57 million
- Price / Sales: 57.99
- Book Value: GBX 0.02 per share
- Price / Book: 6.13
Profitability:- EBIDTA: ($11,740,000.00)
- Net Margins: -584.98%
- Return on Equity: -80.41%
- Return on Assets: -73.81%
Misc:- Average Volume: 157,962 shs.
Frequently Asked Questions for Tissue Regenix Group PLC (LON:TRX)
What is Tissue Regenix Group PLC's stock symbol?
Tissue Regenix Group PLC trades on the London Stock Exchange (LON) under the ticker symbol "TRX."
Where is Tissue Regenix Group PLC's stock going? Where will Tissue Regenix Group PLC's stock price be in 2017?
2 brokers have issued 1 year price objectives for Tissue Regenix Group PLC's shares. Their predictions range from GBX 39 to GBX 39. On average, they anticipate Tissue Regenix Group PLC's share price to reach GBX 39 in the next twelve months. View Analyst Ratings for Tissue Regenix Group PLC.
Who are some of Tissue Regenix Group PLC's key competitors?
Some companies that are related to Tissue Regenix Group PLC include OncoMed Pharmaceuticals (OMED), Asterias Biotherapeutics (AST), Asterias Biotherapeutics (AST), Genocea Biosciences (GNCA), Pluristem Therapeutics (PSTI), CTI BioPharma Corp. (CTIC), Oramed Pharmaceuticals (ORMP), GTx (GTXI), Regulus Therapeutics (RGLS), Silence Therapeutics plc (SLN), Novelion Therapeutics (NVLN), Matinas BioPharma Holdings (MTNB), CASI Pharmaceuticals (CASI), BioLineRx (BLRX), Palatin Technologies (PTN), aTyr Pharma (LIFE), Eiger BioPharmaceuticals (EIGR) and Zynerba Pharmaceuticals (ZYNE).
Who are Tissue Regenix Group PLC's key executives?
Tissue Regenix Group PLC's management team includes the folowing people:
- John Samuel, Executive Chairman of the Board
- Antony Odell, Chief Executive Officer
- Ian David Jefferson, Chief Financial Officer, Executive Director
- Paul John Devlin, Group Finance Director, Company Secretary
- Steven Ashley Couldwell, Non-Executive Director
- Jonathan M. Glenn, Non-Executive Director
- Randeep Singh Grewal, Non-Executive Director
- Shervanthi Homer - Vanniasinkam, Non-Executive Director
- Alan Miller, Non-Executive Director
How do I buy Tissue Regenix Group PLC stock?
Shares of Tissue Regenix Group PLC and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Tissue Regenix Group PLC's stock price today?
One share of Tissue Regenix Group PLC stock can currently be purchased for approximately GBX 12.25.
MarketBeat Community Rating for Tissue Regenix Group PLC (LON TRX)MarketBeat's community ratings are surveys of what our community members think about Tissue Regenix Group PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Tissue Regenix Group PLC (LON:TRX) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 1 Hold Rating, 1 Buy Rating |
| Consensus Rating: | Buy (Score: 2.50) |
| Consensus Price Target: | GBX 39 |
Analysts' Ratings History for Tissue Regenix Group PLC (LON:TRX)
Show:
| Date | Firm | Action | Rating | Price Target | Details |
|---|
| 7/21/2017 | Jefferies Group LLC | Reiterated Rating | Buy | GBX 39 |  |
| 6/5/2017 | Beaufort Securities | Reiterated Rating | Speculative Buy | | |
(Data available from 9/25/2015 forward)
Earnings History for Tissue Regenix Group PLC (LON:TRX)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Tissue Regenix Group PLC (LON:TRX)Current Year EPS Consensus Estimate: $-1.47 EPS
Dividend History for Tissue Regenix Group PLC (LON:TRX)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Tissue Regenix Group PLC (LON:TRX)Insider Trades by Quarter for Tissue Regenix Group PLC (LON:TRX)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 8/9/2017 | John Andrew Samuel | Insider | Buy | 2,000,000 | GBX 10 | £200,000 | |
(Data available from 1/1/2013 forward)
Headline Trends for Tissue Regenix Group PLC (LON:TRX)
Latest Headlines for Tissue Regenix Group PLC (LON:TRX)
| Source: |
|
Tissue Regenix Group PLC (TRX) Chart for Monday, September, 25, 2017
